[Featured Stock] PharmGen Science Hits Upper Limit... MOU with US Company for COVID-19 Vaccine Development
[Asia Economy Reporter Park Soyeon] PharmGen Science is hitting the upper price limit.
As of 2:39 PM on the 23rd, PharmGen Science is trading at 13,650 KRW, up 3,150 KRW (30%) from the previous trading day on the KOSPI market.
PharmGen Science announced on the same day that on the 21st (local time in the US), it attended the "Korea-US Global Vaccine Partnership" hosted by the government in New York, USA, and signed an MOU for "joint development and commercialization of a COVID-19 vaccine" with its US-based subsidiary Access Bio and US venture IVY Pharma.
PharmGen Science was established in 1966 and listed in 1990. Headquartered in Hwaseong, Gyeonggi Province, it is engaged in pharmaceutical manufacturing and wholesale and retail distribution. Its main products include Bardipin, Telodipin, Livatin, Kvastin, Arsidin-F, Esomax, and Neizatin.
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- New Zealand to Cut 8,700 Civil Servants...14% Reduction Deemed 'Unsustainable and Unviable'
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
PharmGen Science has a market capitalization of 200.8 billion KRW and ranks 632nd on the KOSPI.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
